Vertical ridge augmentation by means of deproteinized bovine bone block and recombinant human platelet-derived growth factor-BB: a histologic study in a dog model.
The primary objective of this proof-of-principle study was to evaluate the outcome of vertical ridge augmentation in a standardized dog model by combining purified recombinant platelet-derived growth factor (rhPDGF-BB) and a block of deproteinized cancellous bovine bone. The secondary objective was to determine the value of a resorbable barrier membrane to improve the efficacy of the procedure. Six adult foxhounds were committed to bilateral surgical extraction of all four mandibular premolars. A vertical alveolar ridge defect was created at the time of the extractions. Three months later, the artificially created defects were grafted: Group A used a deproteinized bovine bone block in combination with a collagen barrier membrane, group B used a deproteinized bovine bone block infused with rhPDGF-BB only, and group C included a deproteinized bovine bone block infused with rhPDGF-BB, plus a collagen resorbable barrier membrane. After 4 months, the animals were sacrificed. Histologic examination of group B revealed a large amount of newly formed bone, and a large amount of bone-to-implant contact was visible in the areas of bone regeneration extending over the top of the implant cover screw. The results of this preclinical canine study provide proof-of-principle that rhPDGF-BB, used in combination with a deproteinized bovine block without placement of a barrier membrane, has the potential to regenerate significant amounts of new bone in severe mandibular ridge defects. In addition, the results seem to point to the importance of the periosteum as a source of osteoprogenitor cells in growth factor-mediated regenerative procedures.
Simion
Massimo
M
Department of Periodontology, School of Dentistry, University of Milan, Italy.
Rocchietta
Isabella
I
Kim
David
D
Nevins
Myron
M
Fiorellini
Joseph
J
D020341:Absorbable Implants; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D000818:Animals; D000077214:Becaplermin; D001861:Bone Regeneration / Q000187:drug effects*; D016025:Bone Transplantation; D002417:Cattle; D003758:Dental Implantation, Endosseous; D004285:Dogs; D005260:Female; D016557:Guided Tissue Regeneration, Periodontal; D006801:Humans; D008567:Membranes, Artificial; D023421:Models, Animal; D010521:Periosteum / Q000166:cytology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins / Q000494:pharmacology; D014716:Vertical Dimension
D008567:Membranes, Artificial; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin